 56 PM / Updated 5 minutes ago BRIEF-Tax reform relatively neutral for Mylan-CFO Reuters Staff 
Jan 9 (Reuters) - Mylan: 
* SAYS ITS BIOSIMILAR FOR AMGEN‘S NEULASTA COULD BE A “MID-YEAR OPPORTUNITY” 
* SAYS U.S. TAX REFORM RELATIVELY NEUTRAL FOR THE COMPANY Source text for Eikon: Further company coverage: (Reporting By Michael Erman)